EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyseOpen Access

Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials

Kiran K Thumburu, Meenu Singh, Rashmi Ranjan Das, Nishant Jaiswal, Amit Agarwal, Ajay Kumar, Harpreet Kaur

Therapeutic Advances in Vaccines · 2015

DOI: 10.1177/2051013615575871 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Vaccines, 2015. Verfasst von Kiran K Thumburu und 6 weiteren Autor:innen. Beteiligte Einrichtung: ICMR Advanced Center for Evidence Based Child Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haemophilus influenzae type b (Hib) is an important cause of meningitis and pneumonia in children. Despite the availability of Hib conjugate vaccine, many countries are still to implement it in their immunization schedule. Before introducing the vaccine in routine immunization programs, it is important to know not only the cumulative efficacy but also the efficacy of each vaccine dose. The primary objective of this review is to find whether two primary dose schedule of Hib vaccine is equally efficacious as the standard three primary dose schedule. A highly sensitive online search was run using the terms ‘Haemophilus Vaccines’ or ‘ Haemophilus influenzae type b’ and ‘conjugate vaccine’, and Medline (Ovid), PubMed, Embase, CENTRAL and Scopus were explored for prospective randomized controlled studies. Data were extracted in a predesigned proforma and analyzed using RevMan software. Nine randomized studies were included in the analysis. Pooled vaccine efficacy using a fixed effects model against confirmed invasive Hib disease following the 3, 2 and 1 primary dose schedule were 82% [95% confidence interval (CI) 73-87], 79% (95% CI 54–90) and 65% (95% CI 23–84), respectively, and the overall efficacy was 80% (95% CI 72–85). To conclude, we found that Hib conjugate vaccine is highly efficacious and that the two dose regime is as good as the three dose regime. [The protocol was registered with PROSPERO (CRD42013004490)].

Schlagwörter

Stichwörter der Autor:innen

Haemophilus influenzae type b vaccineefficacyevidencemeta-analysis

Autor:innen und Institutionen

  • ICMR Advanced Center for Evidence Based Child Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
  • Professor, Department of Pediatrics, Advanced Pediatric Centre, PGIMER, Chandigarh-160012, India.
  • Department of Pediatrics, All India Institute of Medical sciences, Bhubaneswar, India.
  • Department of Ophthalmology, Wayne State University, Detroit, MI, USA.
  • University Business School, Punjab University, Chandigarh, India.

Zitieren

APA

Thumburu, K. K., Singh, M., Das, R. R., Jaiswal, N., Agarwal, A., Kumar, A., & Kaur, H. (2015). Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials. Therapeutic Advances in Vaccines. https://doi.org/10.1177/2051013615575871

Vancouver

Thumburu KK, Singh M, Das RR, Jaiswal N, Agarwal A, Kumar A, et al. Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials. Therapeutic Advances in Vaccines. 2015. doi:10.1177/2051013615575871

BibTeX
@article{Thumburu2015,
  author = {Thumburu, Kiran K and Singh, Meenu and Das, Rashmi Ranjan and Jaiswal, Nishant and Agarwal, Amit and Kumar, Ajay and Kaur, Harpreet},
  title = {Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials},
  journal = {Therapeutic Advances in Vaccines},
  year = {2015},
  doi = {10.1177/2051013615575871}
}
Kostenlos starten →